Fig. 4From: Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancerHigh serum ADAM12 levels associate with unfavorable outcome in mesenchymal tumors. Expression of ADAM12 was stratified by molecular subtypes in the AMC-AJCCII-90 dataset, N = 67. Significance is tested by unpaired two tailed Student’s t-test (A). Absolute serum levels of ADAM12 in CAIRO2 FFPE samples stratified by molecular subtypes. N = 146 (B). Serum levels of ADAM12 were dichotomized by ADAM12 levels (222 pg/mL). Survival analysis by Kaplan-Meier is shown for epithelial (CMS2/3) tumors (C) and mesenchymal (CMS4) tumors (D)Back to article page